Boston Scientific Corporation filed an 8-K earnings press release on October 28, 2026, reporting third-quarter 2026 financial results including net sales of $5.138 billion and updated full-year guidance following a cybersecurity incident.

Key Highlights

  • Net sales of $5.138 billion in Q3 2026, up 1.5 percent on a reported, operational, and organic basis compared to the prior year period.
  • GAAP EPS of $0.40 per share, down from $0.51 per share in the prior year period; adjusted EPS of $0.73, compared to $0.75 a year ago.
  • Cardiovascular segment grew 1.9 percent on a reported, operational, and organic basis; MedSurg grew 0.6 percent reported and 0.7 percent operational and organic.
  • LACA region led growth at 16.0 percent reported and 10.5 percent operational; APAC declined 0.6 percent reported and 1.1 percent operational.
  • Full-year 2026 guidance set at approximately 4.25 percent reported net sales growth and approximately 3.75 percent organic net sales growth, with adjusted EPS of $3.16 to $3.18.
  • Q4 2026 net sales expected to decline approximately (3.0) to (1.0) percent on a reported and organic basis, with adjusted EPS of $0.77 to $0.79.
  • Cybersecurity incident acknowledged by CEO Mike Mahoney as a factor in a "challenging year," with teams working to restore operations.

Boston Scientific Q3 2026 Results: Sales Growth Slows After Cybersecurity Incident

According to the filing, Boston Scientific (NYSE:BSX) reported net sales of $5.138 billion for the three months ended September 30, 2026, compared to $5.065 billion in the prior year period. The company disclosed that GAAP net income attributable to common stockholders was $582 million, or $0.40 per share, down from $755 million, or $0.51 per share, a year ago. Adjusted EPS of $0.73 compared to $0.75 in the same prior year period.

The filing breaks down results by segment and region. The Cardiovascular segment recorded net sales of $3.406 billion versus $3.343 billion in Q3 2025, growing 1.9 percent on all three bases. Within MedSurg, Neuromodulation was the standout, growing 13.1 percent on a reported basis to $331 million, while Urology declined 3.2 percent to $661 million and Endoscopy declined 0.8 percent to $741 million. Regionally, LACA grew 16.0 percent reported to $203 million, EMEA grew 4.4 percent reported to $829 million, U.S. grew 0.5 percent to $3.309 billion, and APAC declined 0.6 percent to $797 million, according to the filing.

The company disclosed updated guidance for full-year and fourth-quarter 2026. Full-year net sales growth is now estimated at approximately 4.25 percent on a reported basis and approximately 3.75 percent on an organic basis, with adjusted EPS of $3.16 to $3.18. For Q4 2026, the company estimates a net sales decline of approximately (3.0) to (1.0) percent on a reported and organic basis and adjusted EPS of $0.77 to $0.79. The filing notes that the company has not provided GAAP reconciliations for forward-looking adjusted EPS guidance as it is "unable to predict with reasonable certainty and without unreasonable efforts" the impact of certain charges. The filing also disclosed enrollment commencement in the Elite AF clinical trial for the WATCHMAN Elite device and multiple FDA 510(k) clearances, including for the Navigator Flex Ureteral Access Sheath Set and the LithoVue Elite Single-Use Digital Flexible Ureteroscope with temperature sensing.

What Was Disclosed

Boston Scientific reported Q3 2026 net sales of $5.138 billion, GAAP EPS of $0.40, and adjusted EPS of $0.73, alongside updated full-year and Q4 2026 guidance, segment and regional breakdowns, FDA clearances, and reference to a cybersecurity incident.